Global Familial Amyloid Polyneuropathy Market Research Report 2023

Report ID: 1993292 | Published Date: Jan 2025 | No. of Page: 87 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 FAP-I
        1.2.3 FAP-II
        1.2.4 FAP-III
        1.2.5 FAP-IV
    1.3 Market by Application
        1.3.1 Global Familial Amyloid Polyneuropathy Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospitals and Clinics
        1.3.3 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Familial Amyloid Polyneuropathy Market Perspective (2017-2028)
    2.2 Familial Amyloid Polyneuropathy Growth Trends by Region
        2.2.1 Familial Amyloid Polyneuropathy Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Familial Amyloid Polyneuropathy Historic Market Size by Region (2017-2022)
        2.2.3 Familial Amyloid Polyneuropathy Forecasted Market Size by Region (2023-2028)
    2.3 Familial Amyloid Polyneuropathy Market Dynamics
        2.3.1 Familial Amyloid Polyneuropathy Industry Trends
        2.3.2 Familial Amyloid Polyneuropathy Market Drivers
        2.3.3 Familial Amyloid Polyneuropathy Market Challenges
        2.3.4 Familial Amyloid Polyneuropathy Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue
        3.1.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue (2017-2022)
        3.1.2 Global Familial Amyloid Polyneuropathy Revenue Market Share by Players (2017-2022)
    3.2 Global Familial Amyloid Polyneuropathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Revenue
    3.4 Global Familial Amyloid Polyneuropathy Market Concentration Ratio
        3.4.1 Global Familial Amyloid Polyneuropathy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Revenue in 2021
    3.5 Familial Amyloid Polyneuropathy Key Players Head office and Area Served
    3.6 Key Players Familial Amyloid Polyneuropathy Product Solution and Service
    3.7 Date of Enter into Familial Amyloid Polyneuropathy Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Amyloid Polyneuropathy Breakdown Data by Type
    4.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Type (2017-2022)
    4.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2023-2028)
5 Familial Amyloid Polyneuropathy Breakdown Data by Application
    5.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Application (2017-2022)
    5.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Familial Amyloid Polyneuropathy Market Size (2017-2028)
    6.2 North America Familial Amyloid Polyneuropathy Market Size by Country (2017-2022)
    6.3 North America Familial Amyloid Polyneuropathy Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Familial Amyloid Polyneuropathy Market Size (2017-2028)
    7.2 Europe Familial Amyloid Polyneuropathy Market Size by Country (2017-2022)
    7.3 Europe Familial Amyloid Polyneuropathy Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Familial Amyloid Polyneuropathy Market Size (2017-2028)
    8.2 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Country (2017-2022)
    8.3 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Familial Amyloid Polyneuropathy Market Size (2017-2028)
    9.2 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2017-2022)
    9.3 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Familial Amyloid Polyneuropathy Market Size (2017-2028)
    10.2 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2017-2022)
    10.3 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Pfizer
        11.1.1 Pfizer Company Detail
        11.1.2 Pfizer Business Overview
        11.1.3 Pfizer Familial Amyloid Polyneuropathy Introduction
        11.1.4 Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        11.1.5 Pfizer Recent Development
    11.2 GSK
        11.2.1 GSK Company Detail
        11.2.2 GSK Business Overview
        11.2.3 GSK Familial Amyloid Polyneuropathy Introduction
        11.2.4 GSK Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        11.2.5 GSK Recent Development
    11.3 Ionis
        11.3.1 Ionis Company Detail
        11.3.2 Ionis Business Overview
        11.3.3 Ionis Familial Amyloid Polyneuropathy Introduction
        11.3.4 Ionis Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        11.3.5 Ionis Recent Development
    11.4 Alnylam
        11.4.1 Alnylam Company Detail
        11.4.2 Alnylam Business Overview
        11.4.3 Alnylam Familial Amyloid Polyneuropathy Introduction
        11.4.4 Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        11.4.5 Alnylam Recent Development
    11.5 Corino Therapeutics
        11.5.1 Corino Therapeutics Company Detail
        11.5.2 Corino Therapeutics Business Overview
        11.5.3 Corino Therapeutics Familial Amyloid Polyneuropathy Introduction
        11.5.4 Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        11.5.5 Corino Therapeutics Recent Development
    11.6 Proclara Bioscience
        11.6.1 Proclara Bioscience Company Detail
        11.6.2 Proclara Bioscience Business Overview
        11.6.3 Proclara Bioscience Familial Amyloid Polyneuropathy Introduction
        11.6.4 Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        11.6.5 Proclara Bioscience Recent Development
    11.7 Arcturus Therapeutics
        11.7.1 Arcturus Therapeutics Company Detail
        11.7.2 Arcturus Therapeutics Business Overview
        11.7.3 Arcturus Therapeutics Familial Amyloid Polyneuropathy Introduction
        11.7.4 Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        11.7.5 Arcturus Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of FAP-I
    Table 3. Key Players of FAP-II
    Table 4. Key Players of FAP-III
    Table 5. Key Players of FAP-IV
    Table 6. Global Familial Amyloid Polyneuropathy Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Familial Amyloid Polyneuropathy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Familial Amyloid Polyneuropathy Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Familial Amyloid Polyneuropathy Market Share by Region (2017-2022)
    Table 10. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Familial Amyloid Polyneuropathy Market Share by Region (2023-2028)
    Table 12. Familial Amyloid Polyneuropathy Market Trends
    Table 13. Familial Amyloid Polyneuropathy Market Drivers
    Table 14. Familial Amyloid Polyneuropathy Market Challenges
    Table 15. Familial Amyloid Polyneuropathy Market Restraints
    Table 16. Global Familial Amyloid Polyneuropathy Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Familial Amyloid Polyneuropathy Market Share by Players (2017-2022)
    Table 18. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2021)
    Table 19. Ranking of Global Top Familial Amyloid Polyneuropathy Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Familial Amyloid Polyneuropathy Product Solution and Service
    Table 23. Date of Enter into Familial Amyloid Polyneuropathy Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Familial Amyloid Polyneuropathy Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type (2017-2022)
    Table 27. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type (2023-2028)
    Table 29. Global Familial Amyloid Polyneuropathy Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Familial Amyloid Polyneuropathy Revenue Market Share by Application (2017-2022)
    Table 31. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Familial Amyloid Polyneuropathy Revenue Market Share by Application (2023-2028)
    Table 33. North America Familial Amyloid Polyneuropathy Market Size by Country (2017-2022) & (US$ Million)
    Table 34. North America Familial Amyloid Polyneuropathy Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Europe Familial Amyloid Polyneuropathy Market Size by Country (2017-2022) & (US$ Million)
    Table 36. Europe Familial Amyloid Polyneuropathy Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2017-2022) & (US$ Million)
    Table 38. Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2023-2028) & (US$ Million)
    Table 39. Latin America Familial Amyloid Polyneuropathy Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Latin America Familial Amyloid Polyneuropathy Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Pfizer Company Detail
    Table 44. Pfizer Business Overview
    Table 45. Pfizer Familial Amyloid Polyneuropathy Product
    Table 46. Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 47. Pfizer Recent Development
    Table 48. GSK Company Detail
    Table 49. GSK Business Overview
    Table 50. GSK Familial Amyloid Polyneuropathy Product
    Table 51. GSK Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 52. GSK Recent Development
    Table 53. Ionis Company Detail
    Table 54. Ionis Business Overview
    Table 55. Ionis Familial Amyloid Polyneuropathy Product
    Table 56. Ionis Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 57. Ionis Recent Development
    Table 58. Alnylam Company Detail
    Table 59. Alnylam Business Overview
    Table 60. Alnylam Familial Amyloid Polyneuropathy Product
    Table 61. Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 62. Alnylam Recent Development
    Table 63. Corino Therapeutics Company Detail
    Table 64. Corino Therapeutics Business Overview
    Table 65. Corino Therapeutics Familial Amyloid Polyneuropathy Product
    Table 66. Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 67. Corino Therapeutics Recent Development
    Table 68. Proclara Bioscience Company Detail
    Table 69. Proclara Bioscience Business Overview
    Table 70. Proclara Bioscience Familial Amyloid Polyneuropathy Product
    Table 71. Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 72. Proclara Bioscience Recent Development
    Table 73. Arcturus Therapeutics Company Detail
    Table 74. Arcturus Therapeutics Business Overview
    Table 75. Arcturus Therapeutics Familial Amyloid Polyneuropathy Product
    Table 76. Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 77. Arcturus Therapeutics Recent Development
    Table 78. Research Programs/Design for This Report
    Table 79. Key Data Information from Secondary Sources
    Table 80. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Familial Amyloid Polyneuropathy Market Share by Type: 2021 VS 2028
    Figure 2. FAP-I Features
    Figure 3. FAP-II Features
    Figure 4. FAP-III Features
    Figure 5. FAP-IV Features
    Figure 6. Global Familial Amyloid Polyneuropathy Market Share by Application in 2021 & 2028
    Figure 7. Hospitals and Clinics Case Studies
    Figure 8. Others Case Studies
    Figure 9. Familial Amyloid Polyneuropathy Report Years Considered
    Figure 10. Global Familial Amyloid Polyneuropathy Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Familial Amyloid Polyneuropathy Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Familial Amyloid Polyneuropathy Market Share by Region: 2021 VS 2028
    Figure 13. Global Familial Amyloid Polyneuropathy Market Share by Players in 2021
    Figure 14. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Revenue in 2021
    Figure 16. North America Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 17. North America Familial Amyloid Polyneuropathy Market Share by Country (2017-2028)
    Figure 18. United States Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Canada Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Familial Amyloid Polyneuropathy Market Share by Country (2017-2028)
    Figure 22. Germany Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. France Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. U.K. Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Italy Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Russia Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Nordic Countries Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Familial Amyloid Polyneuropathy Market Share by Region (2017-2028)
    Figure 30. China Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Japan Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. South Korea Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Southeast Asia Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. India Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Australia Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Familial Amyloid Polyneuropathy Market Share by Country (2017-2028)
    Figure 38. Mexico Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Brazil Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Familial Amyloid Polyneuropathy Market Share by Country (2017-2028)
    Figure 42. Turkey Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Saudi Arabia Familial Amyloid Polyneuropathy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Pfizer Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 45. GSK Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 46. Ionis Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 47. Alnylam Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 48. Corino Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 49. Proclara Bioscience Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 50. Arcturus Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation
    Figure 53. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Frequently Asked Questions
Familial Amyloid Polyneuropathy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Familial Amyloid Polyneuropathy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Familial Amyloid Polyneuropathy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports